Biodexa Pharmaceuticals Plc BDRX
Biodexa Pharmaceuticals Plc (Nasdaq: BDRX) is an oncology drug developer. Its lead program, eRapa, is in Phase 3 for Familial adenomatous polyposis (FAP). Its next catalyst on record is eRapa: Biodexa announces the pre-specified futility analysis for its Serenta Phase 3 trial of eRapa in FAP could take place early next year with database lock potentially occurring around the end of next year. (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: eRapa — Biodexa announces the pre-specified futility analysis for its Serenta Phase 3 trial of eRapa in FAP could take place early next year with database lock potentially occurring around the end of next year. (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| eRapa | Familial adenomatous polyposis (FAP) | small molecule | Phase 3 |
| eRapa | Non-muscle invasive bladder cancer (NMIBC) | small molecule | Phase 2 |
| MTX240 (OPB-171775) | GIST | small molecule | Pre-clinical |
Recent results and decisions
- Oct 14, 2026completed enrollment Biodexa enrolled 100 patients in its registrational Phase 3 trial of eRapa in FAP (Serenta trial).
Enrolment of the 100th patient represents an important milestone for Serenta and reflects the continued strong recruitment performance across our participating sites.
Filing - Oct 13, 2026completed enrollment Biodexa enrolled 100 patients in its registrational Phase 3 Serenta trial of eRapa in FAP.
Biodexa Pharmaceuticals PLC is pleased to announce that it has enrolled 100 patients in its registrational Phase 3 trial of eRapa in Familial Adenomatous Polyposis (FAP).
Filing - Nov 3, 2025approval EMA approved the CTA for the Phase 3 Serenta trial in FAP (Denmark, Germany, Netherlands, Spain); ex-US regulatory action.
announced the approval of a Clinical Trial Application (CTA) by the European Medicines Agency (EMA) of its pivotal Phase 3 Serenta trial in patients with familial adenomatous polyposis (FAP)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.